• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2011 Fiscal Year Annual Research Report

末梢血循環腫瘍細胞を用いた肺癌術後再発予測・オーダーメード治療の開発

Research Project

Project/Area Number 21590983
Research InstitutionNiigata University

Principal Investigator

吉澤 弘久  新潟大学, 医歯学総合病院, 准教授 (50282984)

Co-Investigator(Kenkyū-buntansha) 中田 光  新潟大学, 医歯学総合病院, 教授 (80207802)
渡部 聡  新潟大学, 医歯学総合病院, 特任助教 (50529740)
Keywords肺癌 / 末梢血循環腫瘍細胞 / 術後再発
Research Abstract

肺癌患者のcirculating tumor cells (CTC)は術後再発の予測因子と成り得るか?を解析し、さらに術後アジュバント治療のオーダーメード化を目指して研究を進めている。
前年度に実施したCirculating tumor cell高感度検出法の確立のための、EpCAM、抗cytokeratin抗体を含めた単離及び最も感度を高められるビーズ等の条件設定を用いて、肺癌患者におけるCTC定量を試みた。正常白血球細胞とPC9との混合比率は約1/100000まで高められたが、進行期肺癌の末梢血検体での検出率は3%,術後肺癌での検討では検出されなかった。さらなる検出感度の向上のため、現在条件設定を再検討している。またAllele specific PCR、Real time PCRを用いてERCC gene family、β-Tubulin、RRM1の検討についても同様に進めている。

  • Research Products

    (11 results)

All 2011

All Journal Article (6 results) (of which Peer Reviewed: 4 results) Presentation (3 results) Book (2 results)

  • [Journal Article] 肺癌治療薬2011

    • Author(s)
      吉澤弘久
    • Journal Title

      医薬ジャーナル

      Volume: 47 Pages: 180-4

  • [Journal Article] 肺癌化学療法時の悪心・嘔吐の実際2011

    • Author(s)
      田中洋史、吉澤弘久, 他
    • Journal Title

      臨床腫瘍プラクティス

      Volume: 7 Pages: 329-36

  • [Journal Article] Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor2011

    • Author(s)
      Miyabayashi T, Yoshizawa H, et al
    • Journal Title

      Cancer Immunol Immunother

      Volume: 11 Pages: 1597-608

    • DOI

      10.1007/s00262-011-1063-x

    • Peer Reviewed
  • [Journal Article] A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-indue ed nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy2011

    • Author(s)
      Aogi K, Yoshizawa H, et al.
    • Journal Title

      Support Care Cancer

      Volume: 34 Pages: 276-82

    • DOI

      10.1007/s00520-011-1239-0

    • Peer Reviewed
  • [Journal Article] Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations2011

    • Author(s)
      Satoh H, Yoshizawa H, et al.
    • Journal Title

      J Thorac Oncol

      Volume: 8 Pages: 1413-7

    • Peer Reviewed
  • [Journal Article] enoch Schonlein purpura associated with pulmonary adenocarcinoma2011

    • Author(s)
      Mifune D, Yoshizawa H, et al
    • Journal Title

      J Med Case Reports

      Volume: 1 Pages: 226-8

    • DOI

      10.1186/1752-1947-5-226.

    • Peer Reviewed
  • [Presentation] Clinical Responses to EGFR-tyrosine Kinase Inhibitor Retreatment in Non-small Cell Lung Cancer Patients Who Benefited Prior Gefitinib Therapy. Lung cancer Early and Metastatic2011

    • Author(s)
      Watanabe S, Yoshizawa H, et al.
    • Organizer
      European Society for Medical Onocology
    • Place of Presentation
      ストックホルム
    • Year and Date
      2011-09-24
  • [Presentation] DEAD/H (Asp- Glu-Ala-Asp/His) Box Polypeptide 3, X-linked is a CD133+Tumour-specific Protein and Induces Antitumour Immunity2011

    • Author(s)
      Ichikawa K, Yoshizawa H, et al.
    • Organizer
      European Society for Medical Onocology
    • Place of Presentation
      ストックホルム
    • Year and Date
      2011-09-24
  • [Presentation] Efficacy outcome in first-line treatment of advanced NSCLC with gefitinib VS carboplat in/paclitaxel by epidermal growth factor receptor (EGFR)-gene -copy number score and by most common EGFR mutation2011

    • Author(s)
      Yang J, Yoshizawa H, et al.
    • Organizer
      European Society for Medical Onocology
    • Place of Presentation
      ストックホルム
    • Year and Date
      2011-09-24
  • [Book] 呼吸器研修ノート2011

    • Author(s)
      吉澤弘久
    • Total Pages
      840
    • Publisher
      診断と治療社
  • [Book] 肺癌診療Q&A2011

    • Author(s)
      吉澤弘久
    • Total Pages
      343
    • Publisher
      中外医学社

URL: 

Published: 2013-06-26  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi